Navigation Links
Cognitively-impaired human research subjects need better protection
Date:12/7/2010

(Garrison, NY) Practices for protecting human research subjects with Alzheimer's disease and other conditions that make them incapable of giving informed consent are widely variable and in need of more concrete ethical and legal guidance, according to a study in IRB: Ethics & Human Research.

The findings are significant for several reasons. First of all, the authors write, many countries have made research on dementia a national health priority and launched clinical trials that involve people who are, or are likely to become, cognitively impaired. These trials increasingly involve invasive interventions which may pose more than minimal risk. And yet throughout the world, regulations and guidelines provide little direction to ethics review committees about how best to protect these people and about who can make decisions on their behalf.

The new study, part of a larger Canadian research program called Substitute Consent for Research in Elderly Subjects (SCORES), involved telephone interviews with 46 research ethics board chairs in Canada, assessing their attitudes toward enrolling in clinical trials older adults without decision-making capacity and asking what safeguards they would require. Twenty respondents said they had reviewed research protocols involving such persons during the past year and all allowed them to participate in research under certain conditions, such as minimal risks or consent from a substitute decision-maker.

More than half of the ethics board chairs said that they required additional protections for this population, such as assessing decisional capacity. "Yet the fact that some REBs [research ethics boards] did not require these additional safeguards is cause for concern," wrote the researchers. Four allowed older adults without decision-making capacity to participate in minimal risk studies that could benefit them personally, even when there was no one legally authorized to provide substitute consent. The authors raised concerns about this practice, though they acknowledged that the legal requirement regarding substitute consent for research is unclear in the provinces where those REBs are located.

Given the variability in research protections for older adults with cognitive impairment, the researchers "recommend that policy-makers and stakeholders consider developing appropriate protective measures for this population."


'/>"/>

Contact: Michael Turton
turtonm@thehastingscenter.org
845-424-4040 x242
The Hastings Center
Source:Eurekalert

Related medicine news :

1. Species Extinctions May Spell Trouble for Human Health
2. Experts urge US to create emergency cholera vaccine stockpile for humanitarian use
3. Female fish -- and humans? -- lose interest when their male loses a slugfest
4. To be or not to be? Public event examines question of human identity and consciousness
5. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
6. HFES announces Release of Reviews of Human Factors and Ergonomics, Volume 6
7. Rogue gene hijacks stem cells to jumpstart human cancer
8. Scientists Use Tarantulas to Explore Human Fear
9. Dangerous chemicals in food wrappers likely migrating to humans: U of T study
10. Early Humans More Advanced Than Thought
11. Wildlife health reporting tools may help prevent human illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of a pioneering ... , the largest Electronic Medical Records (EMR) provider in South Africa. By using ... a patient’s remote health progress, empowering the patient to take direct responsibility for their ...
(Date:4/26/2017)... Jersey City, NJ (PRWEB) , ... April 26, 2017 , ... ... that offers an easy way to get nutrients from SUPERFOODS! , RawTrition ... the body at the cellular level because the body recognizes its raw form (unlike ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: